ClinicalTrials.gg
Not yet recruitingNCT07528417MYELO-CAN:ABXUpdated Nov 18, 2026

Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)

A Phase 2 interventional study of Levofloxacin and Usual Care in Myeldysplastic Syndrome (MDS), MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET) and Acute Myeloid Leukemia, sponsored by University of Manitoba. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Manitoba · Phase 2, Interventional, and Prevention

How we know

Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 58 studies in Myeloproliferative Disorders with a site in Canada — 11 open to participants now, 23 under way, 7 of them phase 3. Myeloproliferative Disorders · Canada.

Planned enrollment
38th of 54
75 · median 160
Started
2027
the only one that year
Phase 2
17 of 58
6 open now
Primary completion
2028-04
later than 16 of 22 live
Registered
58th of 58
by date
Lead sponsor
2 of 58
University of Manitoba

Among the 58 studies in Myeloproliferative Disorders with a site in Canada, this one is the 38th largest by planned enrollment of the 54 interventional ones that give a count, is the only one that started in 2027, is one of 17 in phase 2, reaches primary completion later than 16 of the 22 other live ones, and was the 58th registered.

Myeloproliferative Disorders

668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.

Browse Myeloproliferative Disorders studies →

Open to participants now

11 of the 58 studies in Myeloproliferative Disorders with a site in Canada are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Myeloproliferative Disorders with a site in Canada, or all of them as a file.
02

Study summary

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life-changing blood cancers. Patients with MDS and AML commonly experience complications related to infection, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of levofloxacin (antibiotic) in MDS and AML patients to safely reduce the risk of infection. In this study 50% of patients will be randomized (like a flip of a coin) to receive levofloxacin and the other 50% will receive usual care (control). The primary objective of the trial is to demonstrate the feasibility of a pragmatic pilot trial necessary to inform our planned phase 3 trial. Additionally, the investigators will monitor both groups of patients to see if the investigators improve the risk and/or severity of infection. Levofloxacin is commonly used in other clinical settings but has not been studied in patients with MDS or AML receiving outpatient chemotherapy (ie, chemotherapy that can be given from clinic, rather than a hospital).

Read the detailed description

STUDY OBJECTIVES: The primary objective of this trial is to demonstrate the feasibility of a pragmatic pilot trial necessary to inform our planned phase 3 trial. TRIAL DESIGN: The investigators will conduct a 75-patient multicentre randomized open-label pilot feasibility trial evaluating levofloxacin versus usual care in patients diagnosed with myelodysplastic syndrome and acute myeloid leukemia receiving outpatient therapy. The intervention group will be levofloxacin 500mg orally daily over the 90-day trial period. Patients will take the levofloxacin daily regardless of their neutrophil count. The control group will be usual care and routine antibiotic prophylaxis is not permitted. OUTCOMES: Our primary outcome will assess the feasibility of a large, multicentre trial of antibiotic prophylaxis in patients with MDS and AML at risk for infectious complications. Our primary measure of feasibility will be the ability to enroll a median of 1 patient per site per month (10 patients / month when all sites are active). SITES AND DURATION: The investigators will initially enroll patients from 10-15 sites across Canada. The expected duration of enrollment is 2 years. SIGNIFICANCE: The trial will evaluate the feasibility of studying antibiotic prophylaxis to optimize supportive care and minimize disease-related complications in patients with MDS and AML. If antibiotic prophylaxis reduces infectious complications, the results of the trial will represent a paradigm shift in how outpatients with MDS and AML are supported and will directly impact practice throughout the world. The initial infrastructure established from this feasibility study will be leveraged to create platform trial infrastructure that will function as a patient-centred learning health system to advance knowledge and improve outcomes for patients with MDS and AML.

03

Conditions studied

  • Myeldysplastic Syndrome (MDS)
  • MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)
  • Acute Myeloid Leukemia

Keywords

  • Levofloxacin
  • Randomized Controlled Trial
  • Myelodysplastic Syndrome
  • Myeloproliferative Neoplasm
  • Acute Myeloid Leukemia
  • Neutropenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Master platform inclusion criteria:

  1. Age ≥ 18 years
  2. Diagnosis of myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, or acute myeloid leukemia

MYELO-CAN ABX inclusion criteria:

1. Initiation of hypomethylating agent-based chemotherapy

Exclusion criteria

Exclusion Criteria:

Master platform exclusion criteria:

  1. Participant is deemed unlikely to survive >30 days (as determined by clinical team)
  2. Participant unable to provide

MYELO-CAN ABX exclusion criteria:

  1. Fever/infection within 1 month of chemotherapy initiation
  2. C-difficile infection within 12 months of chemotherapy initiation
  3. Known sensitivity/allergy to fluoroquinolones
  4. History of tendon disorders related to fluoroquinolone administration
  5. Seizure disorder
  6. Myasthenia gravis
  7. Pregnancy and/or breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Drug: Levofloxacin

  • Active comparator
    Control group

    Other: Usual Care

Interventions

  • This group will receive Levofloxacin 500mg orally daily over the 90-day trial period. Patients will take the levofloxacin daily regardless of their neutrophil count.

  • OtherUsual Care

    This group will receive usual care. Routine antibiotic prophylaxis is not permitted.

06

What researchers measure

Primary outcomes

  1. Patient enrollment feasibility

    Our primary measure of feasibility will be the ability to enroll a median of 1 patient per site per month (10 patients / month when all sites are active).

    Time frame: 2 years

Secondary outcomes

  1. Ability to consent 30% of eligible patients

    The consent rate to be adequate if 30% of eligible patients are enrolled.

    Time frame: 2 years

  2. Protocol adherence

    Protocol adherence to be acceptable provided that 80% of all intended medication doses per patient are administered

    Time frame: 2 years

  3. Off-protocol prophylaxis antibiotic use

    Off-protocol prophylaxis antibiotic use acceptable if \<10% in the control arm

    Time frame: 2 years

  4. Outcome completion

    Outcome completion is adequate if 90% of outcomes are completed

    Time frame: 2 years

  5. Risk of infection

    The risk of infection sufficient if the infectious complication event rate (primary outcome of the phase III trial) is \>30%.

    Time frame: 2 years

Other outcomes

  1. Frequency of febrile neutropenia

    Measure and report the frequency of febrile neutropenia and calculate the mean and median number of febrile neutropenic events per patient.

    Time frame: 2 years

  2. Frequency of hospitalizations due to infection

    Measure the frequency of hospitalizations due to infection and calculate the mean and median number of infection-related hospitalizations per patient.

    Time frame: 2 years

  3. Number of deaths due to infection

    Record the number of deaths due to infection.

    Time frame: 2 years

  4. Frequency of chemotherapy delays

    Measure the frequency of chemotherapy delays of ≥1 week. Calculate the mean and median number of ≥1-week chemotherapy cycle delays per patient.

    Time frame: 3 months

  5. Frequency of chemotherapy cycles with dose reductions

    Measure the frequency of chemotherapy cycles with dose reductions and calculate the mean and median number of chemotherapy cycles with dose reductions per patient.

    Time frame: 3 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Apr 2028, 14 months later.

Of 74 non-industry phase 2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 118. This study's planned 14 months is below that.

Counting every sponsor, half of 87 studies reached it within 68 months; a quarter within 37 and three quarters within 111.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Feb 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 14, 2026
StartEst.
Feb 1, 2027was Sep 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Feb 1, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Sep 1, 2026→Feb 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07528417
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Brett Houston, MD, PhD
Contact
bhouston@cancercare.mb.ca
204-787-8552
Nora Choi, MSc
Contact
nchoi@hsc.mb.ca
204-787-8552

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levofloxacin

Start the discussion